跳至主要内容
临床试验/NCT06178523
NCT06178523已完成4 期

Cost-effective Treatment of Unexplained Infertility: A Prospective Multicenter, Double-blinded, Randomised Controlled Study

Batterjee Medical College1 个研究点 分布在 1 个国家目标入组 900 人开始时间: 2024年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
900
试验地点
1
主要终点
Pregnancy outcome

研究概览

简要总结

The issue of unexplained infertility that Southam brought up in 1960 is still a problem today. Despite improvements in infertility assessment, many couples still don't know why they are infertile. Even with the use of the most advanced ovulation detectors, fallopian tube patency tests, and semen evaluations, competency cannot identify every potential flaw in the intricate processes leading to conception. Unexplained infertility will be a challenge for both biological and clinical researchers since it results from these gaps in our understanding of fertilization and from our incapacity to use all of the current evidence-based information.

详细描述

For the treatment of unexplained infertility, Clomiphene Citrate (CC) is frequently used either alone or in conjunction with intrauterine insemination (IUI). Its combined oestrogenic and anti-oestrogenic characteristics serve as the basis for the mechanism of action. When clomiphene citrate is used, the uterine blood flow is reduced during the peri-implantation stage of early luteal phase. About 80% of women experience ovulation, which has a cumulative effect over 6 to 8 months, yet the pregnancy rate in these women can still be relatively low. The endometrial and cervical mucus-level anti-oestrogenic actions of CC are the potential culprits. Without a doubt, one of the biggest obstacles in treating infertility is the endometrial impact. If the endometrial thickness (ET) is less than 6 mm, the pregnancy rate may be extremely low.

Sildenafil citrate promotes endometrial thickness and uterine blood flow. The capacity of the blastocyst to penetrate the endometrium and establish a lasting blood supply is crucial for successful implantation. To do this, the blastocyst needs genes in order to create the required proteins for breaking down the endometrial cellular matrix, control cell development, and trigger angiogenesis.

It can be difficult to understand the evidence on the efficacy and security of therapy for unexplained infertility. Given the substantial proportion of unaided pregnancies with expectant management, it is problematic that most studies do not include a placebo or untreated control group.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

盲法说明

Double (Clinical investigator; the Radiologist, and Biostatistician; data analyst).

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Saudi women.
  • Married women in a stable, continuous, unprotected heterosexual relationship (cohabitating with their husbands).
  • Aged between 18 to 35 years old.
  • Non-smoking.
  • Non-alcohol drinking.
  • With a body mass index < 30 Kg/M2,
  • Who are looking healthy (all their infertility-workup investigations including male partners' seminal analysis were within normal range)
  • Failed to conceive spontaneously within 2 years of marriage without evident cause (cases with primary infertility).

排除标准

  • All non-Saudi women,
  • Saudi unmarried women (not yet engaged in sexual activity),
  • Married women with age less than 18 or more than 35 years old,
  • Patients with secondary infertility,
  • Cigarette smokers.
  • Alcohol drinking.
  • BMI > 30 Kg/M2,
  • Pregnant women.
  • Breastfeeding women.
  • With known pathological cause (either male or female factor),
  • With hypersensitivity to any of medication planned to be used in the study.

研究组 & 干预措施

Sildenafil & Clomiphene Group

Active Comparator

Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle + Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle.

Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound.

干预措施: Clomiphene Citrate. (Drug)

Sildenafil & Clomiphene Group

Active Comparator

Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle + Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle.

Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound.

干预措施: Sildenafil Citrate (Drug)

IUI & Clomiphene Group

Active Comparator

Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle + Intrauterine insemination (IUI) 42 hours after human chorionic gonadotropin (Pregnyl®) 10,000 IU injection IM.

Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound.

干预措施: Clomiphene Citrate. (Drug)

IUI & Clomiphene Group

Active Comparator

Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle + Intrauterine insemination (IUI) 42 hours after human chorionic gonadotropin (Pregnyl®) 10,000 IU injection IM.

Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound.

干预措施: Intrauterine Insemination (Procedure)

Clomiphene only Group

Placebo Comparator

Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle.

Follow-up by resistance index (RI), pulsatility index (PI), and maximum velocity (T-max) of sub-endometrial, uterine, and ovarian vessels measured by using TVS Colour Doppler ultrasound.

干预措施: Clomiphene Citrate. (Drug)

结局指标

主要结局

Pregnancy outcome

时间窗: 7 weeks after positive pregnancy test.

Ultrasound confirmation of intrauterine fetal heartbeat.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Remah Moustafa Kamel

Professor of Obstetrics and Gynaecology

Batterjee Medical College

研究点 (1)

Loading locations...

相似试验